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Despite the growing number of genome-wide association studies, the involvement of
polymorphisms in microRNA target sites (polymiRTS) in Alzheimer’s disease (AD) remains
poorly investigated. Recently, we have shown that AD-associated single-nucleotide
polymorphisms (SNPs) present in the 3′ untranslated region (3′UTR) of amyloid precursor
protein (APP) could directly affect miRNA function. In theory, loss of microRNA (miRNA)
function could lead to risk for AD by increasing APP expression and Aβ peptide production.
In this study, we tested the hypothesis that Nicastrin, a γ-secretase subunit involved
in Aβ generation, could be regulated by miRNAs, and consequently affected by 3′UTR
polymorphisms. Bioinformatic analysis identiﬁed 22 putativemiRNAbinding sites located in
or near Nicastrin 3′UTRpolymorphisms. From thesemiRNA candidates, sixwere previously
shown to be expressed in human brain. We identiﬁed miR-24, miR-186, and miR-455
as regulators of Nicastrin expression, both in vitro and under physiological conditions in
human cells, which resulted in altered Aβ secretion. Using luciferase-based assays, we
further demonstrated that rs113810300 and rs141849450 SNPs affected miRNA-mediated
repression of Nicastrin. Notably, rs141849450 completely abolished themiR-455-mediated
repression of Nicastrin. Finally, the rs141849450 variant was identiﬁed in 1 out of 511 AD
cases but not in 631 controls.These observations set the stage for future studies exploring
the role of miRNAs and 3′UTR polymorphisms in AD.
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INTRODUCTION
The small, non-coding miRNAs function as important regula-
tors of protein expression (Ambros, 2004). They act by imperfect
base-pairing to target messenger RNAs, leading to translational
repression, degradation, or both (Pillai, 2005). Important for
this action is the seed sequence, located at positions 2–8 within
the miRNA sequence. It is now well documented that speciﬁc
miRNAs are altered in a number of neurodegenerative disor-
ders including Alzheimer’s disease (AD; reviewed in Delay et al.,
2012). These observations evoke the hypothesis that miRNA dys-
regulation could directly be implicated in the disease processes,
either detrimental or as an attempt of neurons to survive. More-
over, increasing evidence suggests that single-nucleotide poly-
morphisms (SNP) within miRNA target sites might contribute
to disease risk. For instance, the Parkinson’s disease-associated
rs12720208 SNP is located in the miR-433 target site of Fibroblast
growth factor 20, and affects miRNA-mediated repression (Wang
et al., 2008). The rs5848 SNP,associatedwithTDP43-positive fron-
totemporal dementias, is located in the miR-659 target site of the
Progranulin gene, also affecting the miRNA-mediated repression
(Rademakers et al., 2008). Previously, we have shown that AD-
associated SNPs present in the untranslated region (3′UTR) of
APP could directly affect miRNA function (Delay et al., 2011). In
theory, loss of miRNA function could contribute signiﬁcantly to
risk forADby increasingAPP expression and thereforeAβproduc-
tion. Aβ peptides are the major constituents of amyloid (senile)
plaques that accumulate in AD brain (Glenner and Wong, 1984).
Another essential player in Aβ production is the γ-secretase
complex, composed of four subunits (i.e., Presenilin, Nicas-
trin, Aph-1, and Pen2; De Strooper, 2003). Recent studies have
documented rare Nicastrin (NCSTN) variants associated with
AD (Lupton et al., 2011), whereas studies in mice have shown
that increased expression of NCSTN is sufﬁcient to promote
AD pathology (Goo et al., 2013). In this study, we evalu-
ated whether miRNAs could modulate NCSTN expression, and
whether polymiRTS within the 3′UTR of the Nicastrin gene could
abrogate miRNA function.
MATERIALS AND METHODS
PATIENTS
Cases of AD and controls were participants from two large Cana-
dian cohorts: theCanadianStudyof Health andAging (CSHA) and
A Canadian Collaborative Cohort of Cognitive Impairment and
Related Dementia (ACCORD). Ethical approval of these studies
was obtained from the ethics review board in each of the study
centers. Details of each cohort have been published elsewhere
Frontiers in Molecular Neuroscience www.frontiersin.org July 2014 | Volume 7 | Article 67 | 1
Delay et al. MicroRNAs regulate Nicastrin expression
(Anonymous, 1994; Feldman et al., 2003; Hsiung et al., 2004).
The clinical examination was developed in collaboration with the
US Consortium to Establish a Registry for Alzheimer’s Disease.
AD cases were diagnosed by NINCDS – ADRDA clinical criteria
(McKhann et al., 1984), and controls were subjects who remained
not cognitively impaired until the end of the study or censorship.
CELL CULTURE
Human HeLa and HEK293-APPSw cells were cultured in DMEM
medium (Invitrogen, Carlsbad, CA, USA) supplemented with
10% heat-inactivated fetal bovine serum. One day before trans-
fection, HeLa cells were plated at 20% conﬂuence in six-well or
24-well plates and 250,000 HEK-APPSw cells were plated into six-
well plates. Transfection was performed using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions.
cDNA CONSTRUCTS
The full-length hNCSTN 3′UTR was extracted by PCR
from SH-SY5Y cells using the following primers: for-
ward: 5′-TTTTTCTAGAGGAGGACCCCAGCTTTTC, reverse
5′-AAAAGGATCCCGTGTGGGATAATCTATTTT,andwere cloned
usingXbaI (NewEnglandBiolabs) andBamHI (NewEnglandBio-
labs) enzymes into the pGL3-promotor vector (Promega, USA).
Mutagenesis was performed by TOPgene technologies (Montreal,
Quebec, Canada) and validated by sequencing.
LUCIFERASE ASSAY AND PROTEIN ANALYSIS
HeLa cells were transfected with 25 or 50 nM pre-miRs (Applied
Biosystems, USA), 2.5 ng/cm2; pRL control vector, and 50 ng/cm2;
pGL3_HSV TK_3′UTR hNCSTN WT or C460T (rs1043329),
T623G (rs113810300) or delCA515–516 (rs141849450) mutant
variant plasmids. Twenty-four hours post-transfection, cells were
lyzed, and luciferase activity was measured according to the
manufacturer’s instructions (Promega, USA). For western blots,
cells were lyzed in RIPA buffer [50 mM Tris HCl, 1% NP40,
0.9% NaCl, 0.25% Na-deoxycholate, 1 mM EDTA, 1× pro-
teinase inhibitors (Roche, Basel, Switzerland), 1 mM PMSF, 1 mM
Na3VO4, and 1 mM NaF], mixed with LDS sample buffer (Invit-
rogen, Carlsbad, CA, USA) containing 5% β-mercapto-ethanol
and boiled at 95◦C for 8 min. Crude extracts (10 μg) were
immunoblotted with the Aph-1a [clone B80.2, kind gift from
B. De Strooper (Nyabi et al., 2003)], Pen2 (Cell Signaling, clone
D2G6), Nicastrin (Cell Signaling, clone D38F9), Presenilin 1
Table 1 | Polymorphisms located in or near miRNA target sites located in the 3′UTR of hNCSTN.
SNPID Position in 3′UTR Polymorphism Predicted microRNA Seed region Number of raw reads
Ts10059 18 C/T hsa-miR-31 Y 0
Ts41266889 196 C/T hsa-miR-3153 Y 0
Ts180769907 360 A/T hsa-miR-1226* Y 0
hsa-miR-608 N 0
hsa-miR-92a* N 0
Ts1043230 367 C/A hsa-miR-92a-2* Y 0
hsa-miR-4298 N 0
Ts1043329 460 C/T hsa-miR-24 N 150
Ts141849450 515–516 delCA hsa-miR-455-5p Y 95
Ts34629439 582 delT hsa-miR-1301 N 45
hsa-miR-590-5p N 11
hsa-miR-27b* N 23
hsa-miR-582-5p N 15
hsa-miR-656 N 107
Ts113810300 623 T/G hsa-miR-1252 Y 0
hsa-miR-3125 Y 0
hsa-miR-340 Y 1708
hsa-miR-142-5p Y 20
hsa-miR-186 Y 1209
hsa-miR-3121 N 0
hsa-miR-4311 N 0
Ts71719087 638/639 delAT hsa-miR-3145 Y 0
The SNP ID and the nature of the polymorphism are indicated. miRNAs which are predicted to interact with the 3′UTR of hNCSTN are listed, and it is noted when the
SNP is located within the seed region of the miRNA in question. Also the number of raw reads (from 1 μg of total RNA) of respective miRNAs in the human cerebral
neocortex is noted (see Anonymous, 1994 for details). Y, yes; N, no.
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(Millipore, clone PS1-loop), and Gapdh (Millipore, clone 6c5)
antibodies. Membranes were detected using the ECL detection kit
(Millipore, Billerica, MA, USA). Quantiﬁcations were performed
using the Multi Gauge software (FUJIFILM, Minato-ku, Tokyo,
Japan).
ELISA
HEK293-APPSw cells were transfected with 50 nM pre-miRs
(Applied Biosystems, USA). Twenty-four hours post-transfection,
cell lysates were collected, spun at 1000 × g for 10 min to remove
debris, and supernatants were kept on ice. Human (soluble)
Aβ1–40 andAβ1–42 peptidesweremeasured usingAβ40 andAβ42
Human ELISA Kits, following the manufacturer’s conditions (Life
Technologies, Carlsbad, CA, USA).
STATISTICS
Statistical signiﬁcance of western blots and luminescence quantiﬁ-
cations was determined using one-wayANOVA, two-wayANOVA,
or Student’s paired t-test as indicated in the text. Calculations were
made using the GraphPad Prism 5 software.
GENOTYPING
DNA was extracted from peripheral blood (AutogenFlex STAR,
Holliston MA, USA), and SNP genotyping was performed with
TaqMan assays in an optimized ABI 7300 (Applied Biosys-
tems). The two SNPs chosen in this study were rs113810300 and
rs141849450 in human Nicastrin.
RESULTS
We ﬁrst used the National Center for Biotechnology Information
(NCBI) database to generate a list of all known SNPs located
within the 3′UTR of human NCSTN (Table 1). In order to
identify SNPs that could affect miRNA binding, we used the
on-line algorithms TargetScan and microRNA.org (Betel et al.,
2008; Garcia et al., 2011). We included both canonical (i.e., per-
fect seed match) and non-canonical (i.e., containing G:U wobbles
or seed mismatches) miRNA binding sites. This analysis resulted
FIGURE 1 | In vitro functional analysis of NCSTN targeting miRNAs.
(A) Schematic representation (not to scale) of the luciferase reporter
construct used in this study (upper panel). TK; thymidine kinase promoter,
AAAA(n); PolyA site, HeLa cells were transfected with 50 nM pre-miRs (as
indicated) as well as a reporter construct containing the untranslated region
(3′UTR) of hNCSTN. The cells were lyzed 24 h post-transfection and
luciferase signal was measured. Signals were normalization for transfection
efﬁciency and graph represents the luciferase signals compared to the
scrambled control (SCR). Statistical signiﬁcance was assessed by one-way
ANOVA with Bonferroni post-hoc test. *p < 0.05. (B) HeLa cells were
transfected with 50 nM pre-miRNAs (as indicated). The cells were lyzed
48 h post-transfection and western blotting was performed. Representative
(n = 3, in triplicate) western blots are shown. The ratios of the
NCSTN/GAPDH signals are presented (both mature and immature NSCTN).
Measurements were normalized to the scrambled control (SCR). Statistical
signiﬁcance was assessed by one-way ANOVA with Bonferroni post-hoc
test. *p < 0.05, **p < 0.01, ***p < 0.001. (C) HeLa cells were transfected
with 50 nM pre-miRNAs (as indicated). The cells were lyzed 48 h
post-transfection and western blotting was performed. Representative
(n = 3, in triplicate) western blots and quantiﬁcations are shown. Statistical
signiﬁcance was assessed by one-way ANOVA with Bonferroni post-hoc
test. ns, not signiﬁcant.
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in a list of 22 miRNAs (Table 1), which we narrowed down to
six (i.e., miR-24, miR-186, miR-340, miR-455, miR-656, and
miR-1301) based on our previous expression proﬁling studies
in the human cerebral neocortex (45 raw reads cut-off; Hébert
et al., 2013). Whether excluded miRNAs are expressed at higher
frequency in other brain regions and/or tissues remains to be
determined.
To validate our bioinformatic analyses, we cloned the full-
length (∼700 bp) 3′UTR of human NCSTN into a luciferase
reporter vector (Figure 1A), and co-transfected this construct
with candidate miRNAs into human HeLa cells. We observed
a signiﬁcant reduction of luciferase expression upon miR-24,
miR-186, and miR-455 expression (Figure 1A) compared to a
scrambled miRNA (SCR) negative control. We also conﬁrmed
the downregulation of endogenous NCSTN after transfection
of candidate miRNAs into HeLa cells (Figure 1B). Notably,
only miR-186 and miR-455 decreased both the mature and
immature forms of NCSTN (Edbauer et al., 2002). While both
miR-340 and miR-656 also affected luciferase and endogenous
NCSTN expression, this observation did not reach signiﬁcance.
Overexpression of identiﬁed NCSTN targeting miRNAs did
not signiﬁcantly affect endogenous Presenilin 1 (PS1), APH1A,
or PEN2 expression (Figure 1C). We thus identiﬁed miR-24,
miR-186, and miR-455 as endogenous regulators of human
NCSTN.
In order to determine the functional consequences of miR-24,
miR-186, and miR-455 expression on Aβ production, we per-
formed ELISA using HEK293-APPSwe cells. Both miR-186 and
miR-455 decreased (soluble) Aβ40 and Aβ42 levels, while miR-24
had a small, nonetheless signiﬁcant effect on Aβ42 (Figure 2). The
observations correlate with our western blot data (Figure 1B),
showing that highest NCSTN repression leads to the lowest Aβ
secretion.
FIGURE 2 | miR-24, miR-186, and miR-455 expression results in
decreased Aβ secretion. Relative quantities of human Aβ40 and Aβ42
peptides measured by ELISA in the culture medium of HEK-APPSwe cells
after transfection with 50 nM pre-miRNAs (as indicated). Signals were
normalized to the basal Aβ secretion found in cells transfected with SCR
miRNAs. Statistical signiﬁcance was assessed by one-way ANOVA with
Bonferroni post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001.
Next, we tested whether these miRNAs were functionally
affected by 3′UTR polymorphisms. To address this, we gen-
erated human NCSTN 3′UTR luciferase constructs containing
the C460T (rs1043329), T623G (rs113810300), or delCA515–516
(rs141849450) variants. As before, these mutant vectors were
co-transfected with candidate miRNAs and luciferase activity
was measured. These screens indicated that the polymorphism
C460T, which is located in the 5′ compensatory region of the
miRNA binding site, did not signiﬁcantly affect miR-24 function
(Figure 3A). On the other hand, both seed region SNPsT623G and
delCA515–516 reduced miR-186 and miR-455-mediated repres-
sion, respectively (Figures 3B–D). It is interesting to note that
both miR-186 and miR-455 have previously been shown to have
an altered expression level in AD cerebrospinal ﬂuid (CSF) sam-
ples, which further underscores the possible association between
these miRNAs and AD development. Taken together, we iden-
tiﬁed miR-186 and miR-455, which are functionally affected by
polymorphisms.
We ﬁnally asked whether identiﬁed SNPs could be associ-
ated with AD. According to the NCBI dbSNP database (February
2014), the rs113810300 SNP has no reported frequency, while
the rs141849450 SNP has a 1/1000 frequency in the European
reference panel (1000 Genomes Phase I V3 SHAPEIT2, Decem-
ber 2013). Using imputation from this latter panel, rs141849450
has an estimated frequency of 5.6/1000 in an independent French
cohort of more than 2000 individuals (data not shown). To vali-
date and extend these observations, we performed TaqMan SNP
genotyping assays in a Canadian patient population of AD cases
and non-demented controls. These screens identiﬁed 1 out of
511 AD individuals harboring the rs141849450 deletion muta-
tion. This individual was aged 65 years and was a carrier of
the APOE4 (e3/e4) allele. Of notice, the rs141849450 SNP was
not present in 631 control. No rs113810300 polymorphism was
identiﬁed in either groups, as everyone was homozygous T/T.
Given the low frequencies of these SNPs in the general popu-
lation, much larger cohorts are required to determine whether
candidate polymorphisms are indeed associatedwith disease. Nev-
ertheless, we identiﬁed at least one SNP co-segregating with anAD
patient, which suggests that rare polymiRTS could contribute to
risk for disease in a subset of patients. In theory, the rs141849450
SNP would lead to increased NCSTN expression and Aβ
load.
DISCUSSION
In the current study, we identiﬁed a number of brain-expressed
miRNAs that could regulate endogenous NCSTN expression and
Aβ peptide production. Furthermore, we identiﬁed rare 3′UTR
polymorphisms that could affect miRNA repressional activity
toward NCSTN, at least in our experimental settings. It has
been demonstrated recently that, besides expression variation
in miRNAs and genetic variants in miRNA loci, polymiRTS
(including both SNPs and small insertions and deletions) are
important sources of expression variation of miRNA target genes
in humans (Gamazon et al., 2012). Moreover, several SNPs that
are in linkage disequilibrium with those that might affect miRNA
binding have been identiﬁed and are associated with the risk
of developing disorders including breast cancer, asthma, and
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FIGURE 3 | SNP delCA 515–516 and SNP T623G reduce miR-455- and
miR-186-mediated NCSTN repression. (A–C) HeLa cells were
transfected with 25 nM pre-miRs (as indicated) as well as a reporter
construct containing the WT, delCA 515–516, T623G and C460T mutated
3′UTR of hNCSTN. The cells were lyzed 24 h post-transfection and
luciferase signal was measured. After normalization for transfection
efﬁciency, the signals were compared to the SCR control. Representative
results (n = 3, performed in triplicate) are shown. Statistical signiﬁcance
was assessed by Student’s paired t -test (*p < 0.05, ***p < 0.001, ns,
not signiﬁcant). SCR; scrambled. (D) Schematic representation of base
pair matching between miRNAs and the 3′UTR of hNCSTN. The seed
region of the miRNAs is indicated. The red bases represent the SNPs
C460T (upper panel), T623G (middle panel), and delCA 515–516 (lower
panel).
Parkinson’s disease (Richardson et al., 2011; Thomas et al., 2011).
These observations provide signiﬁcant evidence for the role of
genetic-variation-mediated regulation by miRNAs in the etiology
of a broad spectrum of human complex phenotypes, including
neurodegenerative diseases, metabolic traits, and autoimmune
disorders. However, whether the SNPs identiﬁed in this study
could also confer risk for AD remains an interesting possibil-
ity but will require extensive follow-up studies in larger cohorts
of patients. Nevertheless, these observations strengthen the
potential role of polymiRTS in neurodegenerative disorders such
as AD.
There are some caveats associated with our study. For instance,
the luciferase reporter system, although a robust, quantita-
tive method of analysis, has limited clinical relevance. Indeed,
the miRNome of immortalized cell lines and a human brain
cell are deﬁnitely different, making it difﬁcult to account for
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compensatory or cumulative effects by other miRNAs on the same
miRNA target site. Secondly, the basal levels of the miRNA of
interest as well as the epigenetics of the region at study might be
different between brain and cell lines, possibly resulting in dif-
ferent responses. Validation in vivo would be more accurate but
would require extensive screening (gene sequencing) studies in
patients with AD. Unfortunately, our Canadian patient samples
were limited to DNA, so we could not perform in vivo Nicastrin
expression studies on mRNA. Another alternative would be to
generate multiple knock-in cell lines or animals (e.g., mice) har-
boring candidate polymorphisms within the endogenous NCSTN
3′UTR, which extends the current scope of this study. It should
be noticed that current mouse models expressing human NCSTN
do not contain the (full) 3′UTR. Moreover, it remains uncertain
if the identiﬁed miRNAs, although expressed in human brain, are
similarly expressed in the mouse brain. Nevertheless, we do pro-
vide functional data in human cells which is in line with our main
hypothesis that speciﬁc miRNAs can regulate Aβ production.
What are the clinical implications of these ﬁndings? As men-
tioned above, this is a notoriously difﬁcult question to answer
given the low frequencies of identiﬁed SNPs (e.g., 5/1000 for
rs141849450) in the general population. These results are some-
what expected and consistent with the notion that functional
3′UTR polymorphisms are uncommon, particularly in the seed
region (Chen and Rajewsky, 2006; Saunders et al., 2007; Yu et al.,
2007), likely because of evolutionary pressure. They are never-
theless important for human disease, as polymiRTS have been
associated with a wide range of diseases, including neurodegen-
erative disorders such as Parkinson’s disease (Wang et al., 2008).
Thus, larger cohorts are required to determine whether candidate
polymorphisms might be associated with AD. Of notice, we also
explored the frequency and possible correlation between Aβ load
and the rs141849450 Nicastrin variant in a large French (Euro-
pean) cohort. Unfortunately, we could not conclude anything
due to the lack of SNP-bearing subjects (unpublished observa-
tions). We do, however, provide experimental validation that the
rs141849450 Nicastrin variant exists in at least one AD patient
(Canadian cohort). This is important since not based only on
prediction algorithms and imputation values. Whether this has
clinical relevance is interesting, but it requires extensive follow-up
studies in much larger cohorts of patients.
In conclusion, we identiﬁed NCSTN-targeting miRNAs (miR-
24, miR-186, and miR-455) that could decrease Aβ secretion.
MiR-186 and miR-455 were previously shown to be altered
in AD CSF samples, and we demonstrated that the miRNA-
mediated repression of NSCTNmRNA is altered by the presence of
SNPs rs113810300 and rs141849450. Our data provide additional
proof of principle that polymiRTS could contribute to neurode-
generative disorders, and that miR-186 and miR-455 could be
important players in AD pathology. We also stress the importance
of including non-translated regions in genome-wide association
studies.
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